Gsa Capital Partners LLP Liquidia Corp Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$6.63 - $9.9 $315,309 - $470,824	47,558 Added 242.87%	67,140 $527,000
Q1 2023 May 12, 2023	BUY	$5.72 - $7.91 $112,009 - $154,893	19,582 New	19,582 $135,000
Q2 2022 Aug 09, 2022	BUY	$3.37 - $7.55 $86,966 - $194,835	25,806 New	25,806 $113,000
Q2 2021 Aug 05, 2021	SELL	$2.51 - $3.11 $226,680 - $280,867	-90,311 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$2.42 - $3.6 $218,552 - $325,119	90,311 New	90,311 $243,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.